These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 31110911)

  • 1. A Phase I/II Placebo-Controlled Randomized Pilot Clinical Trial of Recombinant Deoxyribonuclease (DNase) Eye Drops Use in Patients With Dry Eye Disease.
    Mun C; Gulati S; Tibrewal S; Chen YF; An S; Surenkhuu B; Raju I; Buwick M; Ahn A; Kwon JE; Atassi N; Pradeep A; Rondelli D; Jain S
    Transl Vis Sci Technol; 2019 May; 8(3):10. PubMed ID: 31110911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Randomized Trial of Topical Fibrinogen-Depleted Human Platelet Lysate Treatment of Dry Eye Secondary to Chronic Graft-versus-Host Disease.
    Sugar A; Hussain M; Chamberlain W; Dana R; Kelly DP; Ta C; Irvine J; Daluvoy M; Perez V; Olson J; Jhanji V; Walts TA; Stulting RD; Waller EK; Jagirdar N;
    Ophthalmol Sci; 2022 Sep; 2(3):100176. PubMed ID: 36245754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of novel lipid-based eye drops with aqueous eye drops for dry eye: a multicenter, randomized controlled trial.
    Simmons PA; Carlisle-Wilcox C; Vehige JG
    Clin Ophthalmol; 2015; 9():657-64. PubMed ID: 25931806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Masked Trial of a Topical Estradiol Ophthalmic Formulation in Postmenopausal Women with Moderate-to-Severe Dry Eye Disease.
    Schmidl D; Szalai L; Kiss OG; Schmetterer L; Garhöfer G
    Adv Ther; 2021 Apr; 38(4):1975-1986. PubMed ID: 33710587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Clinical Phase II Study to Assess Efficacy, Safety, and Tolerability of Waterfree Cyclosporine Formulation for Treatment of Dry Eye Disease.
    Wirta DL; Torkildsen GL; Moreira HR; Lonsdale JD; Ciolino JB; Jentsch G; Beckert M; Ousler GW; Steven P; Krösser S
    Ophthalmology; 2019 Jun; 126(6):792-800. PubMed ID: 30703441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 2 randomized, double-masked, placebo-controlled study of novel nonsystemic kinase inhibitor TOP1630 for the treatment of dry eye disease.
    Taylor M; Ousler G; Torkildsen G; Walshe C; Fyfe MCT; Rowley A; Webber S; Sheppard JD; Duggal A
    Clin Ophthalmol; 2019; 13():261-275. PubMed ID: 30858682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy in patients with dry eye after treatment with a new lubricant eye drop formulation.
    Davitt WF; Bloomenstein M; Christensen M; Martin AE
    J Ocul Pharmacol Ther; 2010 Aug; 26(4):347-53. PubMed ID: 20653478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eye.
    Semba CP; Torkildsen GL; Lonsdale JD; McLaurin EB; Geffin JA; Mundorf TK; Kennedy KS; Ousler GW
    Am J Ophthalmol; 2012 Jun; 153(6):1050-60.e1. PubMed ID: 22330307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of 0.15% hylan A eye drops in ameliorating symptoms of severe dry eye patients in Saudi Arabia.
    Alsheikh O; Alzaaidi S; Vargas JM; Al-Sharif E; Alrajeh M; AlSemari MA; Alhommadi A; Alsaati A; Aljwaiser N; Alshahwan E; Abdulhafiz M; Elsayed R; Müller-Lierheim WGK
    Saudi J Ophthalmol; 2021; 35(4):293-298. PubMed ID: 35814996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathological consequences of anti-citrullinated protein antibodies in tear fluid and therapeutic potential of pooled human immune globulin-eye drops in dry eye disease.
    Kwon J; Surenkhuu B; Raju I; Atassi N; Mun J; Chen YF; Sarwar MA; Rosenblatt M; Pradeep A; An S; Dhall N; Mun C; Jain S
    Ocul Surf; 2020 Jan; 18(1):80-97. PubMed ID: 31606460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study.
    Tauber J; Karpecki P; Latkany R; Luchs J; Martel J; Sall K; Raychaudhuri A; Smith V; Semba CP;
    Ophthalmology; 2015 Dec; 122(12):2423-31. PubMed ID: 26365210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of an enhanced viscosity artificial tear for moderate to severe dry eye disease: A multicenter, double-masked, randomized 30-day study.
    Lievens C; Berdy G; Douglass D; Montaquila S; Lin H; Simmons P; Carlisle-Wilcox C; Vehige J; Haque S
    Cont Lens Anterior Eye; 2019 Aug; 42(4):443-449. PubMed ID: 30573298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of clinical outcomes in patients with dry eye disease using lubricant eye drops containing polyethylene glycol or carboxymethylcellulose.
    Cohen S; Martin A; Sall K
    Clin Ophthalmol; 2014; 8():157-64. PubMed ID: 24403819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of recombinant human nerve growth factor eye drops in patients with dry eye: a phase IIa, open label, multiple-dose study.
    Sacchetti M; Lambiase A; Schmidl D; Schmetterer L; Ferrari M; Mantelli F; Allegretti M; Garhoefer G
    Br J Ophthalmol; 2020 Jan; 104(1):127-135. PubMed ID: 30944103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of topical bevacizumab 0.05% eye drops in dry eye disease: A double-masked, randomized trial.
    Kasetsuwan N; Chantaralawan K; Reinprayoon U; Uthaithammarat L
    PLoS One; 2020; 15(6):e0234186. PubMed ID: 32502179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tofacitinib (CP-690,550), a Janus kinase inhibitor for dry eye disease: results from a phase 1/2 trial.
    Liew SH; Nichols KK; Klamerus KJ; Li JZ; Zhang M; Foulks GN
    Ophthalmology; 2012 Jul; 119(7):1328-35. PubMed ID: 22525048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of
    Liu Z; Jin M; Li Y; Liu J; Xiao X; Bi H; Pan Z; Shi H; Xie X; Zhang M; Gao X; Li L; Ouyang W; Tang L; Wu J; Yang Y; Hu J; Liu Z
    J Clin Med; 2020 Dec; 9(12):. PubMed ID: 33322753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topical Omega-3 Polyunsaturated Fatty Acids for the Treatment of Dry Eye - Results from a Pilot Randomized Controlled Masked-Observer Study.
    Kaercher T; Messmer EM; Berninger T; Huber-van der Velden KK; Geiger R; Cipriano-Bonvin P; Jacobi C
    Clin Ophthalmol; 2022; 16():4021-4031. PubMed ID: 36523849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 4-week, randomized, double-masked study to evaluate efficacy of deproteinized calf blood extract eye drops versus sodium hyaluronate 0.3% eye drops in dry eye patients with ocular pain.
    Wu Y; Jin X; Mou Y; Yuan K; Min J; Huang X
    Ann Palliat Med; 2021 Apr; 10(4):3617-3625. PubMed ID: 33615815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autologous serum eye drops for dry eye.
    Pan Q; Angelina A; Marrone M; Stark WJ; Akpek EK
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD009327. PubMed ID: 28245347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.